Global Inflammatory Bowel Disease Treatment Market: Industry Analysis and Forecast (2019-2026) – By Drug Class, Disease Indication, Distribution Channel and Region

Global Inflammatory Bowel Disease Treatment Market size is expected to grow at a CAGR of 7.9% during the forecast period and the market size is expected to reach nearly US$ 27.6 Bn. by 2026. To know about the Research Methodology :- Request Free Sample Report The global inflammatory bowel disease (IBD) is primarily driven by the rising prevalence of inflammatory bowel disease universally, a growing number of drugs in a clinical test and increasing government initiatives for analyzing the causes and effective new drug development are expected factors in this market. Moreover, the higher capital investments essential for drug discovery, insufficient effectiveness of treatment available in the market, and severe drug regulatory policies are restricting the growth in the global market. However, the high prevalence and increasing incidence of Crohn's disease and ulcerative colitis disease in developed conditions has fueled the progress of novel therapeutics drugs are opportunities in the inflammatory bowel disease market during the forecast period. Based on the disease indication, the ulcerative colitis segment is expected to dominate the XX% market share during the forecast period. Ulcerative colitis is a kind of inflammatory bowel disease that mostly impacts the lower area of the body like the rectum. The presence of a robust product pipeline for ulcerative colitis along with current research is expected to initiate segmental growth in the market. Ulcerative colitis is the development of novel therapies for ulcerative colitis treatment and rises in government and non-government organizations towards investigation in biologics further fuel the market growth. The hospital pharmacy segment is to dominate the XX% market share during the forecast period. The increasing number of hospital admittance because of the growing prevalence of ulcerative colitis and Crohn's disease. The established infrastructure of hospitals along with ease of availability of treatment is also improving the development of the hospital pharmacy segment in the inflammatory bowel disease treatment market. Asia-Pacific is expected to account for the largest share of the inflammatory bowel disease treatment market during the forecast period. Asia-Pacific is expected as the fastest-growing inflammatory bowel disease treatment market with an exponential rise in the patient population. Developing countries such as Japan and China are projected to be the largest markets for inflammatory bowel disease treatment in Asia-Pacific. The rising prevalence of stress disorders, anxiety, and the sedentary lifestyles of consumers are expected to outcome an increase in the patient pool is consequently operating the need for treatment drugs. Furthermore, reasonably soft drug regulatory policies and increasing initiatives by the government towards healthcare development are expected to innovativeness in the market during the forecast period. The report covers the recent development in the inflammatory bowel disease treatment market in March 2019, Johnson & Johnson Services Inc. broadcasted novel data from its Phase III UNIFI review performance positive results of STELARA in the grown person suffering from moderate to severe ulcerative colitis. The objective of the report is to present a comprehensive analysis of Global Inflammatory Bowel Disease Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Inflammatory Bowel Disease Treatment Market dynamics, structure by analysing the market segments and project the Global Inflammatory Bowel Disease Treatment Market size. Clear representation of competitive analysis of key players by Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Inflammatory Bowel Disease Treatment Market make the report investor’s guide. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Scope of the Global Inflammatory Bowel Disease Treatment Market: Inquire before buying

Global Inflammatory Bowel Disease Treatment Market, By Drug Class

• TNF (Tumor Necrosis Factor)Inhibitors • Aminosalicyclates • Immunomodulators • Corticosteroids • Biologics • Antibiotics

Global Inflammatory Bowel Disease Treatment Market, By Disease Indication

• Ulcerative Colitis • Crohn’s Disease

Global Inflammatory Bowel Disease Treatment Market, By Distribution Channel

• Hospital Pharmacy • Retail Pharmacy • Online Pharmacy

Global Inflammatory Bowel Disease Treatment Market, By Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Key players operating in the Global Inflammatory Bowel Disease Treatment Market

• Abbott Laboratories • Valeant Pharmaceuticals International • Novartis AG • Janssen Biotech Inc. • Alkem Laboratories Limited • AbbVie Inc. • UCB Inc • Takeda Pharmaceutical Company Limited • Biogen Inc. • Pfizer Inc. • Allergan plc • Celltrion Healthcare • Innovate Biopharmaceuticals • Gilead Sciences • Johnson & Johnson Services Inc. • CELGENE CORPORATION • COSMO PHARMACEUTICALS • B&W Tek • Agilent Technologies, Inc • PG Instruments Limited
Global Inflammatory Bowel Disease Treatment Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Inflammatory Bowel Disease Treatment Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Inflammatory Bowel Disease Treatment Market Analysis and Forecast 6.1. Global Inflammatory Bowel Disease Treatment Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Inflammatory Bowel Disease Treatment Market Analysis and Forecast, by Drug Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Drug Class 7.4. Global Inflammatory Bowel Disease Treatment Market Size (US$ Bn) Forecast, by Drug Class 7.5. Global Inflammatory Bowel Disease Treatment Market Analysis, by Drug Class 7.6. Global Inflammatory Bowel Disease Treatment Market Attractiveness Analysis, by Drug Class 8. Global Inflammatory Bowel Disease Treatment Market Analysis and Forecast, by Disease Indication 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Disease Indication 8.4. Global Inflammatory Bowel Disease Treatment Market Size (US$ Bn) Forecast, by Disease Indication 8.5. Global Inflammatory Bowel Disease Treatment Market Analysis, by Disease Indication 8.6. Global Inflammatory Bowel Disease Treatment Market Attractiveness Analysis, by Disease Indication 9. Global Inflammatory Bowel Disease Treatment Market Analysis and Forecast, by Distribution Channel 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Distribution Channel 9.4. Global Inflammatory Bowel Disease Treatment Market Size (US$ Bn) Forecast, by Distribution Channel 9.5. Global Inflammatory Bowel Disease Treatment Market Analysis, by Distribution Channel 9.6. Global Inflammatory Bowel Disease Treatment Market Attractiveness Analysis, by Distribution Channel 10. Global Inflammatory Bowel Disease Treatment Market Analysis, by Region 10.1. Global Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Region 10.2. Global Inflammatory Bowel Disease Treatment Market Size (US$ Bn) Forecast, by Region 10.3. Global Inflammatory Bowel Disease Treatment Market Attractiveness Analysis, by Region 11. North America Inflammatory Bowel Disease Treatment Market Analysis 11.1. Key Findings 11.2. North America Inflammatory Bowel Disease Treatment Market Overview 11.3. North America Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Drug Class 11.4. North America Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 11.4.1. TNF (Tumor Necrosis Factor)Inhibitors 11.4.2. Aminosalicyclates 11.4.3. Immunomodulators 11.4.4. Corticosteroids 11.4.5. Biologics 11.4.6. Antibiotics 11.5. North America Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Disease Indication 11.6. North America Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 11.6.1. Ulcerative Colitis 11.6.2. Crohn’s Disease 11.7. North America Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Distribution Channel 11.8. North America Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 11.8.1. Hospital Pharmacy 11.8.2. Retail Pharmacy 11.8.3. Online Pharmacy 11.9. North America Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Country 11.10. North America Inflammatory Bowel Disease Treatment Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Inflammatory Bowel Disease Treatment Market Analysis, by Country 11.12. U.S. Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 11.12.1. TNF (Tumor Necrosis Factor)Inhibitors 11.12.2. Aminosalicyclates 11.12.3. Immunomodulators 11.12.4. Corticosteroids 11.12.5. Biologics 11.12.6. Antibiotics 11.13. U.S. Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 11.13.1. Ulcerative Colitis 11.13.2. Crohn’s Disease 11.14. U.S. Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 11.14.1. Hospital Pharmacy 11.14.2. Retail Pharmacy 11.14.3. Online Pharmacy 11.15. Canada Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 11.15.1. TNF (Tumor Necrosis Factor)Inhibitors 11.15.2. Aminosalicyclates 11.15.3. Immunomodulators 11.15.4. Corticosteroids 11.15.5. Biologics 11.15.6. Antibiotics 11.16. Canada Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 11.16.1. Ulcerative Colitis 11.16.2. Crohn’s Disease 11.17. Canada Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 11.17.1. Hospital Pharmacy 11.17.2. Retail Pharmacy 11.17.3. Online Pharmacy 11.18. North America Inflammatory Bowel Disease Treatment Market Attractiveness Analysis 11.18.1. By Drug Class 11.18.2. By Disease Indication 11.18.3. By Distribution Channel 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Inflammatory Bowel Disease Treatment Market Analysis 12.1. Key Findings 12.2. Europe Inflammatory Bowel Disease Treatment Market Overview 12.3. Europe Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Drug Class 12.4. Europe Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 12.4.1. TNF (Tumor Necrosis Factor)Inhibitors 12.4.2. Aminosalicyclates 12.4.3. Immunomodulators 12.4.4. Corticosteroids 12.4.5. Biologics 12.4.6. Antibiotics 12.5. Europe Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Disease Indication 12.6. Europe Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 12.6.1. Ulcerative Colitis 12.6.2. Crohn’s Disease 12.7. Europe Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Distribution Channel 12.8. Europe Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 12.8.1. Hospital Pharmacy 12.8.2. Retail Pharmacy 12.8.3. Online Pharmacy 12.9. Europe Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Country 12.10. Europe Inflammatory Bowel Disease Treatment Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Inflammatory Bowel Disease Treatment Market Analysis, by Country 12.12. Europe Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 12.12.1. TNF (Tumor Necrosis Factor)Inhibitors 12.12.2. Aminosalicyclates 12.12.3. Immunomodulators 12.12.4. Corticosteroids 12.12.5. Biologics 12.12.6. Antibiotics 12.13. Germany Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 12.13.1. Ulcerative Colitis 12.13.2. Crohn’s Disease 12.14. Germany Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 12.14.1. Hospital Pharmacy 12.14.2. Retail Pharmacy 12.14.3. Online Pharmacy 12.15. U.K. Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 12.15.1. TNF (Tumor Necrosis Factor)Inhibitors 12.15.2. Aminosalicyclates 12.15.3. Immunomodulators 12.15.4. Corticosteroids 12.15.5. Biologics 12.15.6. Antibiotics 12.16. U.K. Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 12.16.1. Ulcerative Colitis 12.16.2. Crohn’s Disease 12.17. U.K. Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 12.17.1. Hospital Pharmacy 12.17.2. Retail Pharmacy 12.17.3. Online Pharmacy 12.18. France Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 12.18.1. TNF (Tumor Necrosis Factor)Inhibitors 12.18.2. Aminosalicyclates 12.18.3. Immunomodulators 12.18.4. Corticosteroids 12.18.5. Biologics 12.18.6. Antibiotics 12.19. France Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 12.19.1. Ulcerative Colitis 12.19.2. Crohn’s Disease 12.20. France Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 12.20.1. Hospital Pharmacy 12.20.2. Retail Pharmacy 12.20.3. Online Pharmacy 12.21. Italy Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 12.21.1. TNF (Tumor Necrosis Factor)Inhibitors 12.21.2. Aminosalicyclates 12.21.3. Immunomodulators 12.21.4. Corticosteroids 12.21.5. Biologics 12.21.6. Antibiotics 12.22. Italy Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 12.22.1. Ulcerative Colitis 12.22.2. Crohn’s Disease 12.23. Italy Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 12.23.1. Hospital Pharmacy 12.23.2. Retail Pharmacy 12.23.3. Online Pharmacy 12.24. Spain Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 12.24.1. TNF (Tumor Necrosis Factor)Inhibitors 12.24.2. Aminosalicyclates 12.24.3. Immunomodulators 12.24.4. Corticosteroids 12.24.5. Biologics 12.24.6. Antibiotics 12.25. Spain Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 12.25.1. Ulcerative Colitis 12.25.2. Crohn’s Disease 12.26. Spain Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 12.26.1. Hospital Pharmacy 12.26.2. Retail Pharmacy 12.26.3. Online Pharmacy 12.27. Rest of Europe Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 12.27.1. TNF (Tumor Necrosis Factor)Inhibitors 12.27.2. Aminosalicyclates 12.27.3. Immunomodulators 12.27.4. Corticosteroids 12.27.5. Biologics 12.27.6. Antibiotics 12.28. Rest of Europe Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 12.28.1. Ulcerative Colitis 12.28.2. Crohn’s Disease 12.29. Rest Of Europe Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 12.29.1. Hospital Pharmacy 12.29.2. Retail Pharmacy 12.29.3. Online Pharmacy 12.30. Europe Inflammatory Bowel Disease Treatment Market Attractiveness Analysis 12.30.1. By Drug Class 12.30.2. By Disease Indication 12.30.3. By Distribution Channel 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Inflammatory Bowel Disease Treatment Market Analysis 13.1. Key Findings 13.2. Asia Pacific Inflammatory Bowel Disease Treatment Market Overview 13.3. Asia Pacific Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Drug Class 13.4. Asia Pacific Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 13.4.1. TNF (Tumor Necrosis Factor)Inhibitors 13.4.2. Aminosalicyclates 13.4.3. Immunomodulators 13.4.4. Corticosteroids 13.4.5. Biologics 13.4.6. Antibiotics 13.5. Asia Pacific Inflammatory Bowel Disease Treatment Market Value Share Analysis, By Disease Indication 13.6. Asia Pacific Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 13.6.1. Ulcerative Colitis 13.6.2. Crohn’s Disease 13.7. Asia Pacific Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Distribution Channel 13.8. Asia Pacific Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 13.8.1. Hospital Pharmacy 13.8.2. Retail Pharmacy 13.8.3. Online Pharmacy 13.9. Asia Pacific Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Country 13.10. Asia Pacific Inflammatory Bowel Disease Treatment Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Inflammatory Bowel Disease Treatment Market Analysis, by Country 13.12. China Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 13.12.1. TNF (Tumor Necrosis Factor)Inhibitors 13.12.2. Aminosalicyclates 13.12.3. Immunomodulators 13.12.4. Corticosteroids 13.12.5. Biologics 13.12.6. Antibiotics 13.13. China Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 13.13.1. Ulcerative Colitis 13.13.2. Crohn’s Disease 13.14. China Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 13.14.1. Hospital Pharmacy 13.14.2. Retail Pharmacy 13.14.3. Online Pharmacy 13.15. India Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 13.15.1. TNF (Tumor Necrosis Factor)Inhibitors 13.15.2. Aminosalicyclates 13.15.3. Immunomodulators 13.15.4. Corticosteroids 13.15.5. Biologics 13.15.6. Antibiotics 13.16. India Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 13.16.1. Ulcerative Colitis 13.16.2. Crohn’s Disease 13.17. India Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 13.17.1. Hospital Pharmacy 13.17.2. Retail Pharmacy 13.17.3. Online Pharmacy 13.18. Japan Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 13.18.1. TNF (Tumor Necrosis Factor)Inhibitors 13.18.2. Aminosalicyclates 13.18.3. Immunomodulators 13.18.4. Corticosteroids 13.18.5. Biologics 13.18.6. Antibiotics 13.19. Japan Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 13.19.1. Ulcerative Colitis 13.19.2. Crohn’s Disease 13.20. Japan Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 13.20.1. Hospital Pharmacy 13.20.2. Retail Pharmacy 13.20.3. Online Pharmacy 13.21. ASEAN Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 13.21.1. TNF (Tumor Necrosis Factor)Inhibitors 13.21.2. Aminosalicyclates 13.21.3. Immunomodulators 13.21.4. Corticosteroids 13.21.5. Biologics 13.21.6. Antibiotics 13.22. ASEAN Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 13.22.1. Ulcerative Colitis 13.22.2. Crohn’s Disease 13.23. ASEAN Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 13.23.1. Hospital Pharmacy 13.23.2. Retail Pharmacy 13.23.3. Online Pharmacy 13.24. Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 13.24.1. TNF (Tumor Necrosis Factor)Inhibitors 13.24.2. Aminosalicyclates 13.24.3. Immunomodulators 13.24.4. Corticosteroids 13.24.5. Biologics 13.24.6. Antibiotics 13.25. Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 13.25.1. Ulcerative Colitis 13.25.2. Crohn’s Disease 13.26. Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 13.26.1. Hospital Pharmacy 13.26.2. Retail Pharmacy 13.26.3. Online Pharmacy 13.27. Asia Pacific Inflammatory Bowel Disease Treatment Market Attractiveness Analysis 13.27.1. By Drug Class 13.27.2. By Disease Indication 13.27.3. By Distribution Channel 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Inflammatory Bowel Disease Treatment Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Inflammatory Bowel Disease Treatment Market Overview 14.3. Middle East & Africa Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Drug Class 14.4. Middle East & Africa Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 14.4.1. TNF (Tumor Necrosis Factor)Inhibitors 14.4.2. Aminosalicyclates 14.4.3. Immunomodulators 14.4.4. Corticosteroids 14.4.5. Biologics 14.4.6. Antibiotics 14.5. Middle East & Africa Inflammatory Bowel Disease Treatment Market Value Share Analysis, By Disease Indication 14.6. Middle East & Africa Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 14.6.1. Ulcerative Colitis 14.6.2. Crohn’s Disease 14.7. Middle East & Africa Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Distribution Channel 14.8. Middle East & Africa Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 14.8.1. Hospital Pharmacy 14.8.2. Retail Pharmacy 14.8.3. Online Pharmacy 14.9. Middle East & Africa Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Country 14.10. Middle East & Africa Inflammatory Bowel Disease Treatment Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Inflammatory Bowel Disease Treatment Market Analysis, by Country 14.12. GCC Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 14.12.1. TNF (Tumor Necrosis Factor)Inhibitors 14.12.2. Aminosalicyclates 14.12.3. Immunomodulators 14.12.4. Corticosteroids 14.12.5. Biologics 14.12.6. Antibiotics 14.13. GCC Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 14.13.1. Ulcerative Colitis 14.13.2. Crohn’s Disease 14.14. GCC Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 14.14.1. Hospital Pharmacy 14.14.2. Retail Pharmacy 14.14.3. Online Pharmacy 14.15. South Africa Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 14.15.1. TNF (Tumor Necrosis Factor)Inhibitors 14.15.2. Aminosalicyclates 14.15.3. Immunomodulators 14.15.4. Corticosteroids 14.15.5. Biologics 14.15.6. Antibiotics 14.16. South Africa Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 14.16.1. Ulcerative Colitis 14.16.2. Crohn’s Disease 14.17. South Africa Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 14.17.1. Hospital Pharmacy 14.17.2. Retail Pharmacy 14.17.3. Online Pharmacy 14.18. Rest of Middle East & Africa Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 14.18.1. TNF (Tumor Necrosis Factor)Inhibitors 14.18.2. Aminosalicyclates 14.18.3. Immunomodulators 14.18.4. Corticosteroids 14.18.5. Biologics 14.18.6. Antibiotics 14.19. Rest of Middle East & Africa Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 14.19.1. Ulcerative Colitis 14.19.2. Crohn’s Disease 14.20. Rest of Middle East & Africa Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 14.20.1. Hospital Pharmacy 14.20.2. Retail Pharmacy 14.20.3. Online Pharmacy 14.21. Middle East & Africa Inflammatory Bowel Disease Treatment Market Attractiveness Analysis 14.21.1.1. By Drug Class 14.21.1.2. By Disease Indication 14.21.1.3. By Distribution Channel 14.21.1.4. PEST Analysis 14.21.1.5. Key Trends 14.21.1.6. Key Developments 15. South America Inflammatory Bowel Disease Treatment Market Analysis 15.1. Key Findings 15.2. South America Inflammatory Bowel Disease Treatment Market Overview 15.3. South America Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Drug Class 15.4. South America Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 15.4.1. TNF (Tumor Necrosis Factor)Inhibitors 15.4.2. Aminosalicyclates 15.4.3. Immunomodulators 15.4.4. Corticosteroids 15.4.5. Biologics 15.4.6. Antibiotics 15.5. South America Inflammatory Bowel Disease Treatment Market Value Share Analysis, By Disease Indication 15.6. South America Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 15.6.1. Ulcerative Colitis 15.6.2. Crohn’s Disease 15.7. South America Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Distribution Channel 15.8. South America Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 15.8.1. Hospital Pharmacy 15.8.2. Retail Pharmacy 15.8.3. Online Pharmacy 15.9. South America Inflammatory Bowel Disease Treatment Market Value Share Analysis, by Country 15.10. South America Inflammatory Bowel Disease Treatment Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Inflammatory Bowel Disease Treatment Market Analysis, by Country 15.12. Brazil Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 15.12.1. TNF (Tumor Necrosis Factor)Inhibitors 15.12.2. Aminosalicyclates 15.12.3. Immunomodulators 15.12.4. Corticosteroids 15.12.5. Biologics 15.12.6. Antibiotics 15.13. Brazil Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 15.13.1. Ulcerative Colitis 15.13.2. Crohn’s Disease 15.14. Brazil Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 15.14.1. Hospital Pharmacy 15.14.2. Retail Pharmacy 15.14.3. Online Pharmacy 15.15. Mexico Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 15.15.1. TNF (Tumor Necrosis Factor)Inhibitors 15.15.2. Aminosalicyclates 15.15.3. Immunomodulators 15.15.4. Corticosteroids 15.15.5. Biologics 15.15.6. Antibiotics 15.16. Mexico Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 15.16.1. Ulcerative Colitis 15.16.2. Crohn’s Disease 15.17. Mexico Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 15.17.1. Hospital Pharmacy 15.17.2. Retail Pharmacy 15.17.3. Online Pharmacy 15.17.3.1. Contract Manufacturing Organizations 15.18. Rest of South America Inflammatory Bowel Disease Treatment Market Forecast, by Drug Class 15.18.1. TNF (Tumor Necrosis Factor)Inhibitors 15.18.2. Aminosalicyclates 15.18.3. Immunomodulators 15.18.4. Corticosteroids 15.18.5. Biologics 15.18.6. Antibiotics 15.19. Rest of South America Inflammatory Bowel Disease Treatment Market Forecast, by Disease Indication 15.19.1. Ulcerative Colitis 15.19.2. Crohn’s Disease 15.20. Rest of South America Inflammatory Bowel Disease Treatment Market Forecast, by Distribution Channel 15.20.1. Hospital Pharmacy 15.20.2. Retail Pharmacy 15.20.3. Online Pharmacy 15.21. South America Inflammatory Bowel Disease Treatment Market Attractiveness Analysis 15.21.1. By Drug Class 15.21.2. By Disease Indication 15.21.3. By Distribution Channel 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Abbott Laboratories 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Valeant Pharmaceuticals International 16.3.3. Novartis AG 16.3.4. Janssen Biotech Inc. 16.3.5. Alkem Laboratories Limited 16.3.6. AbbVie Inc. 16.3.7. UCB Inc 16.3.8. Takeda Pharmaceutical Company Limited 16.3.9. Biogen Inc. 16.3.10. Pfizer Inc. 16.3.11. Allergan plc 16.3.12. Celltrion Healthcare 16.3.13. Innovate Biopharmaceuticals 16.3.14. Gilead Sciences 16.3.15. Johnson & Johnson Services Inc. 16.3.16. CELGENE CORPORATION 16.3.17. COSMO PHARMACEUTICALS 16.3.18. B&W Tek 16.3.19. Agilent Technologies, Inc 16.3.20. PG Instruments Limited 17. Primary Key Insights

About This Report

Report ID 39027
Category Healthcare
Published Date Dec 2019
Updated Date Aug 2020
Contact Us